방사선의학 웹진

바로가기  >

Abstract
This study evaluated the efficacy and safety of 20.0 Gy versus 30.6 Gy radiotherapy for conjunctival MALT lymphoma in 76 lesions treated between 2010 and 2022. The 30.6 Gy group showed a shorter median time to response (3.7 vs. 9.5 months, p < 0.001) and a higher complete response rate at 6 months (68.4% vs. 36.8%, p = 0.009). However, both doses achieved 100% local control at two years. Radiation-induced complications were minimal, with no grade 3 or higher events, and cataracts occurred in only 5.3% of patients in both groups. These results indicate that reducing the radiation dose to 20.0 Gy can achieve comparable long-term outcomes with minimal toxicity, offering an effective treatment alternative for localized conjunctival MALT lymphoma.

Affiliations

Jaeha Lee 1, Si Yeol Song 1, Young Seob Shin 1, Sung-Woo Kim 1, Ye Jin Yoo 1, Ji Hyeon Joo 2, Ho-Seok Sa 3, Dok Hyun Yoon 4, Sang-Wook Lee 1
1Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
2Department of Radiation Oncology, Pusan National University School of Medicine, Yangsan, Republic of Korea.
3Department of Ophthalmology, University of Ulsan College of Medicine, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
4Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.